{"id":2180,"date":"2024-09-24T14:10:16","date_gmt":"2024-09-24T11:10:16","guid":{"rendered":"https:\/\/www.welovecycling.com\/ee\/?p=2180"},"modified":"2024-09-24T14:10:16","modified_gmt":"2024-09-24T11:10:16","slug":"kaalulangetusravimid-on-need-ka-tohusad","status":"publish","type":"post","link":"https:\/\/www.welovecycling.com\/ee\/2024\/09\/24\/kaalulangetusravimid-on-need-ka-tohusad\/","title":{"rendered":"Kaalulangetusravimid \u2013 on need ka t\u00f5husad?"},"content":{"rendered":"<p><strong>Kaalulangetustablettide maine on olnud halb. Nende m\u00f5ju oli \u00fclehinnatud, puudus teaduslik t\u00f5endus ning nad sisaldasid isegi ohtlikke aineid. \u00d5nneks ei kehti see enam praeguse p\u00f5lvkonna kaalulangetusravimite kohta. Vaatame selliseid GLP-1 agonistidega ravimeid nagu Ozempic, Wegovy v\u00f5i Rybelsus \u2013 kui t\u00f5husad need on?<\/strong><\/p>\n<p><!--more--><\/p>\n<h3><strong>GLP-1 rohtude taga on palju uuringuid<\/strong><\/h3>\n<p>Praegusi kaalulangetustablette tuntakse kui GLP-1 agoniste, sest need aimavad j\u00e4rele hormooni GLP-1 (gl\u00fckagoonilaadne peptiid-1). Hormoon avastati 1980ndatel aastatel ning teadlased leidsid, et see suurendas insuliini eritumist ning aeglustas mao t\u00fchjenemist, osutudes seet\u00f5ttu huvitavaks diabeedi ja rasvumise ravil.<\/p>\n<p>Veel m\u00f5nik\u00fcmmend aastat uuringuid ja 2005. aastal j\u00f5udis turule esimene USA f\u00f6deraalse ravimiameti FDA heakskiiduga GLP-1 ravim eksenatiid (Byetta), mis oli m\u00f5eldud teise t\u00fc\u00fcbi diabeedi raviks. Aga alles aastal 2017 muutusid sedalaadi ravimid populaarseks, kui FDA kiitis heaks semaglutiidi (Ozempic). Menu peamine p\u00f5hjus oli, et Ozempicut tuleb tarvitada ainult kord n\u00e4dalas, pakkudes patsientidele sellega mugavust ja paremat ravisoostumust.<\/p>\n<h3><strong>Kuidas rasvumisvastased ravimid t\u00f6\u00f6tavad?<\/strong><\/h3>\n<p>Nende kaalulangetusravimite m\u00f5istmiseks tuleb vaadata, kuidas need m\u00f5jutavad meie keha ja vaimu toidu m\u00f5ttes. GLP-1 funktsiooni j\u00e4rele aimates on neil kolm m\u00f5ju:<\/p>\n<ul>\n<li>Nad panevad k\u00f5hun\u00e4\u00e4rme insuliini tootma, mis aitab reguleerida <a href=\"https:\/\/www.welovecycling.com\/wide\/2022\/04\/14\/the-nordic-diet-lowers-cholesterol-and-blood-sugar-should-you-try-it\/\">veresuhkrut<\/a> ning tekitada s\u00f6\u00f6mise j\u00e4rel t\u00e4isk\u00f5hu tunnet.<\/li>\n<li>Nad aeglustavad mao t\u00fchjenemist ja toidu liikumist soolestikus, mis samuti aitab pikendada t\u00e4isk\u00f5hutunnet s\u00f6\u00f6mise j\u00e4rel.<\/li>\n<li>Nad m\u00f5jutavad aju, v\u00e4hendades s\u00f6\u00f6giisu ja toidum\u00fcra \u2013 pealet\u00fckkivaid m\u00f5tteid s\u00f6\u00f6gist.<\/li>\n<\/ul>\n<p>K\u00f5ik need kolm protsessi toimuvad meis k\u00f5igis ka t\u00e4nu GLP-1 hormooni looduslikule tootmisele. Probleem on aga selles, et \u00fclekaaluliste inimeste keha l\u00f5hustab kiiresti oma GLP-1, mist\u00f5ttu see on v\u00e4hem t\u00f5hus. Seet\u00f5ttu l\u00e4hebki neil kauem t\u00e4isk\u00f5hutunde tekkimisega, nad muutuvad kiiremini n\u00e4ljaseks ja tunnevad peaaegu pidevat toidum\u00fcra. Sellised ravimid nagu Ozempic annavad kehale s\u00fcnteetilist GLP-1 hormooni, mis p\u00fcsib palju kauem ja leevendab neid takistusi, mida rasvunud inimesed kogevad.<\/p>\n<h3><strong>Kui t\u00f5husad on GLP-1 ravimid?<\/strong><\/h3>\n<p><a href=\"https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2032183\">Uuring n\u00e4itas<\/a>, et umbes 86 protsenti \u00fclekaalulistest v\u00f5i rasvunud inimestest, kes v\u00f5tavad selliseid GLP-1 ravimeid nagu Ozempic, Wegovy v\u00f5i Rybelsus, kaotavad v\u00e4hemalt viis protsenti kehakaalust. Ning umbes kolmandik neist kaotab \u00fcle 20 protsendi kehakaalust. Nende ravimite uuema p\u00f5lvkonna versioonid, n\u00e4iteks tirzepatiid, on veelgi perspektiivikamad. <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2206038\">Uuringud n\u00e4itasid<\/a> et kuni 57 protsenti neid ravimeid manustanud inimestest kaotas \u00fcle 20 protsendi kehakaalust.<\/p>\n<h3><strong>Kaalulangetusravimid v\u00f5rrelduna elustiili muutustega<\/strong><\/h3>\n<p>Elustiili muudatuste ja juhendatud treeningutega kaotavad inimesed keskmiselt 5\u201313 protsenti kehakaalust. See on p\u00e4ris muljetavaldav, sest hakkama saadakse ilma rohtude ja k\u00f5rvalm\u00f5judeta. Kuid pole \u00f5ige lihtsalt k\u00f5rvutada neid arve kaalulangetusravimite uuringute protsentidega. P\u00f5hjus on siin: elustiili sekkumine ja kaalulangetusravimid koos annavad tavaliselt tulemuseks veel 10 protsenti t\u00e4iendavat kehakaalu langust.<\/p>\n<h3><strong>Uus uuring lubab veelgi enam t\u00f5husust koos v\u00e4hemate k\u00f5rvalm\u00f5judega<\/strong><\/h3>\n<p><a href=\"https:\/\/www.jci.org\/articles\/view\/178250\">Kaalulangetusravimite uuringud<\/a> j\u00e4tkuvad t\u00e4ie auruga. \u00dcks hiljutine teadust\u00f6\u00f6 tuvastas ajus melanokortiin-3 retseptori (MC3R), mille p\u00e4rssimine v\u00f5ib parandada reaktsiooni GLP-1 agonistidele. Esialgsed katsed hiirtega n\u00e4itavad, et GLP-1 ravimid koos MC3R antagonistidega v\u00f5ivad suurendada ravimite soovitud m\u00f5ju tundlikkust kuni viis korda ilma soovimatuid k\u00f5rvalm\u00f5jusid tugevdamata. See v\u00f5ib aidata patsientidel, kes on tundlikud GLP-1 ravimite k\u00f5rvalm\u00f5judele, v\u00f5tta neid m\u00e4rksa v\u00e4iksemas koguses, saavutades samal ajal palju paremaid tulemusi.<\/p>\n<p>Kokkuv\u00f5ttes on praeguse p\u00f5lvkonna kaalulangetusravimid v\u00e4ga t\u00f5husad ja annavad tulemuseks m\u00e4rkimisv\u00e4\u00e4rse kehakaalu languse, eriti koos elustiili muudatustega. Uuringud lubavad edasisigi edusamme. Seet\u00f5ttu nimetavad m\u00f5ned inimesed kaalulangetusravimeid petmiseks. Vaatame seda k\u00fcsimust j\u00e4rgmises artiklis.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kaalulangetustablettide maine on olnud halb. Nende m\u00f5ju oli \u00fclehinnatud, puudus teaduslik t\u00f5endus ning nad sisaldasid isegi ohtlikke aineid. \u00d5nneks ei [&hellip;]<\/p>\n","protected":false},"author":174,"featured_media":2181,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[43],"tags":[288,291,292,289,290,293],"global-categories":[22],"class_list":["post-2180","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tervis-trenn","tag-glp-1","tag-ozempic","tag-rybelsus","tag-ulekaalulisus","tag-ulekaalulisuse-ravim","tag-wegovy","global-categories-cycling"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.3 (Yoast SEO v25.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Kaalulangetusravimid \u2013 on need ka t\u00f5husad? - \u0160koda We Love Cycling - Estonia<\/title>\n<meta name=\"description\" content=\"Kaalulangetustablettide maine on olnud halb. Nende m\u00f5ju oli \u00fclehinnatud, puudus teaduslik t\u00f5endus ning nad sisaldasid isegi ohtlikke aineid. \u00d5nneks ei kehti see enam praeguse p\u00f5lvkonna kaalulangetusravimite kohta. Vaatame selliseid GLP-1 agonistidega ravimeid nagu Ozempic, Wegovy v\u00f5i Rybelsus \u2013 kui t\u00f5husad need on?\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.welovecycling.com\/ee\/2024\/09\/24\/kaalulangetusravimid-on-need-ka-tohusad\/\" \/>\n<meta property=\"og:locale\" content=\"et_EE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kaalulangetusravimid \u2013 on need ka t\u00f5husad?\" \/>\n<meta property=\"og:description\" content=\"Kaalulangetustablettide maine on olnud halb. Nende m\u00f5ju oli \u00fclehinnatud, puudus teaduslik t\u00f5endus ning nad sisaldasid isegi ohtlikke aineid. \u00d5nneks ei kehti see enam praeguse p\u00f5lvkonna kaalulangetusravimite kohta. Vaatame selliseid GLP-1 agonistidega ravimeid nagu Ozempic, Wegovy v\u00f5i Rybelsus \u2013 kui t\u00f5husad need on?\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.welovecycling.com\/ee\/2024\/09\/24\/kaalulangetusravimid-on-need-ka-tohusad\/\" \/>\n<meta property=\"og:site_name\" content=\"\u0160koda We Love Cycling - Estonia\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-24T11:10:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/d2p6e6u75xmxt8.cloudfront.net\/15\/2024\/09\/kaal1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"891\" \/>\n\t<meta property=\"og:image:height\" content=\"590\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"andre\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ji\u0159\u00ed Kalo\u010d\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.welovecycling.com\/ee\/2024\/09\/24\/kaalulangetusravimid-on-need-ka-tohusad\/\",\"url\":\"https:\/\/www.welovecycling.com\/ee\/2024\/09\/24\/kaalulangetusravimid-on-need-ka-tohusad\/\",\"name\":\"Kaalulangetusravimid \u2013 on need ka t\u00f5husad? - \u0160koda We Love Cycling - Estonia\",\"isPartOf\":{\"@id\":\"https:\/\/www.welovecycling.com\/ee\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.welovecycling.com\/ee\/2024\/09\/24\/kaalulangetusravimid-on-need-ka-tohusad\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.welovecycling.com\/ee\/2024\/09\/24\/kaalulangetusravimid-on-need-ka-tohusad\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/d2p6e6u75xmxt8.cloudfront.net\/15\/2024\/09\/kaal1.webp\",\"datePublished\":\"2024-09-24T11:10:16+00:00\",\"author\":{\"@id\":\"https:\/\/www.welovecycling.com\/ee\/#\/schema\/person\/8b7101c4bd1b1ae9d3732ebb1e6caf57\"},\"description\":\"Kaalulangetustablettide maine on olnud halb. Nende m\u00f5ju oli \u00fclehinnatud, puudus teaduslik t\u00f5endus ning nad sisaldasid isegi ohtlikke aineid. \u00d5nneks ei kehti see enam praeguse p\u00f5lvkonna kaalulangetusravimite kohta. Vaatame selliseid GLP-1 agonistidega ravimeid nagu Ozempic, Wegovy v\u00f5i Rybelsus \u2013 kui t\u00f5husad need on?\",\"inLanguage\":\"et\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.welovecycling.com\/ee\/2024\/09\/24\/kaalulangetusravimid-on-need-ka-tohusad\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"et\",\"@id\":\"https:\/\/www.welovecycling.com\/ee\/2024\/09\/24\/kaalulangetusravimid-on-need-ka-tohusad\/#primaryimage\",\"url\":\"https:\/\/d2p6e6u75xmxt8.cloudfront.net\/15\/2024\/09\/kaal1.webp\",\"contentUrl\":\"https:\/\/d2p6e6u75xmxt8.cloudfront.net\/15\/2024\/09\/kaal1.webp\",\"width\":891,\"height\":590},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.welovecycling.com\/ee\/#website\",\"url\":\"https:\/\/www.welovecycling.com\/ee\/\",\"name\":\"\u0160koda We Love Cycling - Estonia\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.welovecycling.com\/ee\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"et\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.welovecycling.com\/ee\/#\/schema\/person\/8b7101c4bd1b1ae9d3732ebb1e6caf57\",\"name\":\"andre\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"et\",\"@id\":\"https:\/\/www.welovecycling.com\/ee\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0656b3224fe17b018f43b8a562625dd43d30827f027b2f62bc5a05711fec9a61?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0656b3224fe17b018f43b8a562625dd43d30827f027b2f62bc5a05711fec9a61?s=96&d=mm&r=g\",\"caption\":\"andre\"},\"url\":\"https:\/\/www.welovecycling.com\/ee\/author\/andre\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kaalulangetusravimid \u2013 on need ka t\u00f5husad? - \u0160koda We Love Cycling - Estonia","description":"Kaalulangetustablettide maine on olnud halb. Nende m\u00f5ju oli \u00fclehinnatud, puudus teaduslik t\u00f5endus ning nad sisaldasid isegi ohtlikke aineid. \u00d5nneks ei kehti see enam praeguse p\u00f5lvkonna kaalulangetusravimite kohta. Vaatame selliseid GLP-1 agonistidega ravimeid nagu Ozempic, Wegovy v\u00f5i Rybelsus \u2013 kui t\u00f5husad need on?","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.welovecycling.com\/ee\/2024\/09\/24\/kaalulangetusravimid-on-need-ka-tohusad\/","og_locale":"et_EE","og_type":"article","og_title":"Kaalulangetusravimid \u2013 on need ka t\u00f5husad?","og_description":"Kaalulangetustablettide maine on olnud halb. Nende m\u00f5ju oli \u00fclehinnatud, puudus teaduslik t\u00f5endus ning nad sisaldasid isegi ohtlikke aineid. \u00d5nneks ei kehti see enam praeguse p\u00f5lvkonna kaalulangetusravimite kohta. Vaatame selliseid GLP-1 agonistidega ravimeid nagu Ozempic, Wegovy v\u00f5i Rybelsus \u2013 kui t\u00f5husad need on?","og_url":"https:\/\/www.welovecycling.com\/ee\/2024\/09\/24\/kaalulangetusravimid-on-need-ka-tohusad\/","og_site_name":"\u0160koda We Love Cycling - Estonia","article_published_time":"2024-09-24T11:10:16+00:00","og_image":[{"width":891,"height":590,"url":"https:\/\/d2p6e6u75xmxt8.cloudfront.net\/15\/2024\/09\/kaal1.webp","type":"image\/webp"}],"author":"andre","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ji\u0159\u00ed Kalo\u010d","Est. reading time":"4"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.welovecycling.com\/ee\/2024\/09\/24\/kaalulangetusravimid-on-need-ka-tohusad\/","url":"https:\/\/www.welovecycling.com\/ee\/2024\/09\/24\/kaalulangetusravimid-on-need-ka-tohusad\/","name":"Kaalulangetusravimid \u2013 on need ka t\u00f5husad? - \u0160koda We Love Cycling - Estonia","isPartOf":{"@id":"https:\/\/www.welovecycling.com\/ee\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.welovecycling.com\/ee\/2024\/09\/24\/kaalulangetusravimid-on-need-ka-tohusad\/#primaryimage"},"image":{"@id":"https:\/\/www.welovecycling.com\/ee\/2024\/09\/24\/kaalulangetusravimid-on-need-ka-tohusad\/#primaryimage"},"thumbnailUrl":"https:\/\/d2p6e6u75xmxt8.cloudfront.net\/15\/2024\/09\/kaal1.webp","datePublished":"2024-09-24T11:10:16+00:00","author":{"@id":"https:\/\/www.welovecycling.com\/ee\/#\/schema\/person\/8b7101c4bd1b1ae9d3732ebb1e6caf57"},"description":"Kaalulangetustablettide maine on olnud halb. Nende m\u00f5ju oli \u00fclehinnatud, puudus teaduslik t\u00f5endus ning nad sisaldasid isegi ohtlikke aineid. \u00d5nneks ei kehti see enam praeguse p\u00f5lvkonna kaalulangetusravimite kohta. Vaatame selliseid GLP-1 agonistidega ravimeid nagu Ozempic, Wegovy v\u00f5i Rybelsus \u2013 kui t\u00f5husad need on?","inLanguage":"et","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.welovecycling.com\/ee\/2024\/09\/24\/kaalulangetusravimid-on-need-ka-tohusad\/"]}]},{"@type":"ImageObject","inLanguage":"et","@id":"https:\/\/www.welovecycling.com\/ee\/2024\/09\/24\/kaalulangetusravimid-on-need-ka-tohusad\/#primaryimage","url":"https:\/\/d2p6e6u75xmxt8.cloudfront.net\/15\/2024\/09\/kaal1.webp","contentUrl":"https:\/\/d2p6e6u75xmxt8.cloudfront.net\/15\/2024\/09\/kaal1.webp","width":891,"height":590},{"@type":"WebSite","@id":"https:\/\/www.welovecycling.com\/ee\/#website","url":"https:\/\/www.welovecycling.com\/ee\/","name":"\u0160koda We Love Cycling - Estonia","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.welovecycling.com\/ee\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"et"},{"@type":"Person","@id":"https:\/\/www.welovecycling.com\/ee\/#\/schema\/person\/8b7101c4bd1b1ae9d3732ebb1e6caf57","name":"andre","image":{"@type":"ImageObject","inLanguage":"et","@id":"https:\/\/www.welovecycling.com\/ee\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/0656b3224fe17b018f43b8a562625dd43d30827f027b2f62bc5a05711fec9a61?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0656b3224fe17b018f43b8a562625dd43d30827f027b2f62bc5a05711fec9a61?s=96&d=mm&r=g","caption":"andre"},"url":"https:\/\/www.welovecycling.com\/ee\/author\/andre\/"}]}},"_links":{"self":[{"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/posts\/2180","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/users\/174"}],"replies":[{"embeddable":true,"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/comments?post=2180"}],"version-history":[{"count":2,"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/posts\/2180\/revisions"}],"predecessor-version":[{"id":2183,"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/posts\/2180\/revisions\/2183"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/media\/2181"}],"wp:attachment":[{"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/media?parent=2180"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/categories?post=2180"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/tags?post=2180"},{"taxonomy":"global-categories","embeddable":true,"href":"https:\/\/www.welovecycling.com\/ee\/wp-json\/wp\/v2\/global-categories?post=2180"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}